Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy: An Enabling Strategy for Bioactive Supramolecular Chirality Construction
Top Cited Papers
- 26 June 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 20 (8), 5844-5852
- https://doi.org/10.1021/acs.nanolett.0c01757
Abstract
The design of bioactive supramolecular chirality is always hampered by the lack of feasible schemes to assigned specific biological activities. Herein, we developed a ‘mirror-image peptide grafting’ method to graft the epitopes of bioactive D-peptide onto the miniprotein template to construct a self-assembled supraparticle. Grafting DPMIβ, a 12-mer D-enantiomeric peptide functioned as the p53 agonist, onto Apamin, we successfully constructed a self-assembled D-enantiomeric miniprotein supermolecule nanoparticle, termed DMSN. This chiral supraparticle possesses favorable pharmaceutical profile including the passive tumor targeting, cell membrane penetration, intracellular reductive responsiveness, endosome escaping. DMSN showed in vitro and in vivo p53-dependent antiproliferative activity, and augmented antitumor immunity elicited by anti-PD1 therapy. This enabling strategy will allow us to fabricate a class of peptide/protein-derived supramolecular chirality with predictable biological activities, and will likely have a broad impact on the chiral nanotechnology at the service of prevention and treatment of human diseases.Funding Information
- Ministry of Education of the People's Republic of China (1191319101)
- China Postdoctoral Science Foundation (BX20190278)
- Natural Science Foundation of Shaanxi Province (2020JQ-092)
- Thousand Talents Plan of Shaanxi Province
- Xi'an Jiaotong University
- Institutional Science Foundation of The First Affiliated Hospital of Xi'an Jiaotong University (2019QN-01)
This publication has 50 references indexed in Scilit:
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasmsProceedings of the National Academy of Sciences of the United States of America, 2010
- A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 InteractionAngewandte Chemie, 2010
- Metal-Directed Protein Self-AssemblyAccounts of Chemical Research, 2010
- Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53Angewandte Chemie, 2009
- Role of Asn2 and Glu7 residues in the oxidative folding and on the conformation of the N‐terminal loop of apaminPeptide Science, 2007
- Nanoimprint Lithography: Methods and Material RequirementsAdvanced Materials, 2007
- Drug Chirality and its Clinical SignificanceDrugs, 1996
- p21 is a universal inhibitor of cyclin kinasesNature, 1993